In this multicenter retrospective study, it was observed that, in HR + HER2− advanced breast cancer patients progressing under CDK 4/6 inhibitor therapy, a short duration of CDK4/6 inhibitor treatment increased physicians’ preference for chemotherapy as a subsequent treatment. The gene discussed is CDK4; the disease is breast cancer.